Elizabeth M Jaffee Selected Research

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

1/2021	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint.
10/2020	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
1/2020	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
1/2020	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
9/2019	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
1/2019	Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
3/2016	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.
12/2015	TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
4/2015	Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
1/2015	Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elizabeth M Jaffee Research Topics

Disease

133	Neoplasms (Cancer) 11/2022 - 01/2003
45	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 08/2004
37	Adenocarcinoma 01/2022 - 12/2007
15	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2003
13	Neoplasm Metastasis (Metastasis) 11/2022 - 04/2011
8	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 12/2007
7	Melanoma (Melanoma, Malignant) 01/2022 - 01/2013
4	Colonic Neoplasms (Colon Cancer) 01/2021 - 11/2014
4	Hypersensitivity (Allergy) 10/2014 - 02/2005
3	Bites and Stings (Sting) 01/2021 - 01/2017
2	Triple Negative Breast Neoplasms 11/2022 - 01/2020
2	COVID-19 01/2022 - 01/2021
2	Margins of Excision 01/2021 - 01/2018
2	Carcinogenesis 01/2020 - 04/2015
2	Microsatellite Instability 10/2019 - 11/2017
2	Inflammation (Inflammations) 12/2017 - 07/2013
2	Lymphopenia (Lymphocytopenia) 07/2017 - 04/2015
2	Carcinoma (Carcinomatosis) 04/2015 - 08/2003
2	Barrett Esophagus (Barrett's Esophagus) 11/2008 - 01/2008
2	Esophageal Neoplasms (Esophageal Cancer) 11/2008 - 01/2008
2	Renal Cell Carcinoma (Grawitz Tumor) 07/2005 - 02/2005
1	Neoplasm Micrometastasis 01/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 10/2021
1	Autoimmune Diseases (Autoimmune Disease) 07/2021

Drug/Important Bio-Agent (IBA)

56	VaccinesIBA 01/2022 - 01/2003
26	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021 - 08/2003
25	AntigensIBA 12/2021 - 09/2003
21	Cancer VaccinesIBA 10/2020 - 07/2003
14	Neoplasm Antigens (Tumor Antigens)IBA 12/2021 - 01/2003
13	AntibodiesIBA 11/2022 - 04/2011
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2014
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2003
11	Immune Checkpoint InhibitorsIBA 01/2022 - 09/2013
10	MesothelinIBA 01/2020 - 08/2004
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 05/2005
8	IpilimumabIBA 11/2021 - 07/2013
8	CytokinesIBA 01/2020 - 01/2005
7	Pharmaceutical PreparationsIBA 11/2022 - 01/2005
7	Monoclonal AntibodiesIBA 11/2022 - 08/2003
7	Peptides (Polypeptides)IBA 01/2021 - 04/2003
6	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2018
6	Annexin A2 (Annexin II)IBA 01/2019 - 04/2011
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 09/2008
5	EpitopesIBA 01/2015 - 04/2003
4	NivolumabIBA 11/2021 - 01/2015
4	Trastuzumab (Herceptin)FDA Link 10/2014 - 08/2003
3	Histone Deacetylase InhibitorsIBA 01/2022 - 12/2018
3	entinostat (MS 275)IBA 01/2022 - 12/2018
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 07/2021 - 01/2012
3	InterferonsIBA 01/2021 - 01/2015
3	LigandsIBA 01/2020 - 01/2015
3	pembrolizumabIBA 01/2020 - 01/2015
3	Gemcitabine FDA Link 11/2017 - 07/2011
2	Drug CombinationsIBA 11/2022 - 04/2017
2	Biological ProductsIBA 01/2022 - 08/2005
2	COVID-19 VaccinesIBA 01/2022 - 01/2021
2	Small Cytoplasmic RNAIBA 11/2021 - 10/2019
2	atezolizumabIBA 10/2021 - 01/2021
2	B7-H1 AntigenIBA 01/2021 - 01/2020
2	Metformin (Glucophage)FDA LinkGeneric 05/2020 - 04/2015
2	ChemokinesIBA 01/2020 - 01/2018
2	Programmed Cell Death 1 ReceptorIBA 01/2020 - 01/2020
2	Mitogen-Activated Protein KinasesIBA 01/2019 - 09/2012
2	AnnexinsIBA 01/2019 - 04/2011
2	amatuximabIBA 12/2016 - 12/2007
2	GVAX vaccineIBA 12/2015 - 01/2015
2	Oncogene Proteins (Oncogene Protein)IBA 04/2015 - 09/2007
2	sipuleucel-T (APC8015)FDA Link 01/2015 - 07/2013
1	Interleukin-8 (Interleukin 8)IBA 11/2022
1	Interleukin-6 (Interleukin 6)IBA 11/2022
1	Bispecific AntibodiesIBA 11/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Immunomodulating AgentsIBA 12/2021
1	Immunoglobulin E (IgE)IBA 12/2021
1	OvalbuminIBA 12/2021
1	cobimetinibIBA 10/2021
1	Non-Receptor Type 22 Protein Tyrosine PhosphataseIBA 07/2021
1	selicrelumabIBA 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2021
1	Hyaluronic Acid (Hyaluronan)IBA 01/2021
1	durvalumabIBA 01/2021
1	MethyltransferasesIBA 01/2021
1	HydrogelsIBA 01/2021
1	guadecitabineIBA 01/2021
1	avelumabIBA 01/2021
1	Sirolimus (Rapamycin)FDA Link 05/2020
1	Keratins (Keratin)IBA 01/2020

Therapy/Procedure

58	Immunotherapy 01/2022 - 09/2003
57	Therapeutics 11/2022 - 07/2003
15	Drug Therapy (Chemotherapy) 01/2022 - 09/2003
6	Radiotherapy 01/2018 - 10/2010
5	Precision Medicine 01/2022 - 11/2017
2	Intravenous Injections 02/2019 - 02/2012
2	Aftercare (After-Treatment) 01/2015 - 01/2015
1	Molecular Targeted Therapy 01/2022
1	Immunomodulation 10/2021
1	Adjuvant Chemotherapy 01/2021
1	Induction Chemotherapy 05/2020